Xeltis raises 鈧�20.5 million for medical implants
Eindhoven-based company and 黑料福利网 spin-off Xeltis aims to use new funding to secure approval in the U.S. and facilitate further growth.
Eindhoven-based company and 黑料福利网 spin-off Xeltis aims to use new funding to secure approval in the U.S. and facilitate further growth.
Forming new blood vessels
With this new investment, aims to complete the final phase of a major U.S. clinical trial. This implant was developed for patients who require hemodialysis, a treatment in which an artificial kidney machine cleanses the blood of people whose kidneys no longer function properly. The implant is designed to enable the body to form new, living blood vessels on its own. In addition, the company will use the funds to expand production, launch the product commercially in Europe, and further develop other medical programs.
Confidence in the technology
According to Eliane Schutte, Chief Executive Officer of Xeltis, the investment demonstrates confidence in the company鈥檚 technology. 鈥淭his fundraising not only enables us to bring our groundbreaking vascular access technology to more European patients, as we continue our successful commercial rollout, but also enables us to advance our aXess鈩� pivotal trial in the US, prepare for US market launch and continue our other exciting clinical programs, XABG and XPAD.
Funding follows previous investment
The new funding follows a 鈧�50 million investment that Xeltis secured in 2025 from, among others, the European Investment Bank and existing shareholders.
The investment round was led by new investor Horizon 3 Healthcare. Existing investors such as the European Innovation Council, Invest-NL, EQT Life Sciences, and other shareholders also participated.
Nieuws
